Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.38 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5991067 | 0.94 | SMN1; SMN2 (0.56) | MAPK14SMN1; SMN2NOD1CXCL8GAA | |
| SCHEMBL4830340 | 0.86 | MAPK14 (0.39) | MAPK14NOD1CXCL8GAANOD2 | |
| SCHEMBL11149114 | 0.83 | MAPK14 (0.47) | MAPK14SMN1; SMN2NOD1CXCL8GAA | |
| SCHEMBL991522 | 0.80 | PI4KB (0.57) | MAPK14PI4KBCYP3A4 | |
| SCHEMBL11157062 | 0.80 | MAPK14 (0.45) | MAPK14SMN1; SMN2NOD1CXCL8GAA | |
| SCHEMBL11246875 | 0.80 | PI4KB (0.46) | MAPK14SMN1; SMN2NOD1CXCL8GAA | |
| SCHEMBL11262610 | 0.80 | PI4KB (0.48) | MAPK14SMN1; SMN2NOD1CXCL8PI4KB | |
| SCHEMBL990147 | 0.79 | SMN1; SMN2 (0.69) | MAPK14SMN1; SMN2NOD1CXCL8GAA | |
| SCHEMBL14247717 | 0.77 | MAPK14 (0.45) | MAPK14NOD1CXCL8GAANOD2 | |
| SCHEMBL11625701 | 0.77 | MAPK14 (0.44) | MAPK14SMN1; SMN2PI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012174312-A2 | BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | MAPK14 10/4885SMN1; SMN2 4631/4885NOD1 1591/4885 |
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | MAPK14 341/4885SMN1; SMN2 3611/4885NOD1 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.